The latest results from the Phase III KEYNOTE-942 trial mark a major step forward in the evolution of personalised cancer immunotherapy. The study demonstrates that adding the tailored mRNA vaccine mRNA-4157 (also known as V940) to pembrolizumab significantly improves outcomes for patients with resected high-risk melanoma. Specifically, the combination reduced the risk of recurrence or death by 44% compared to pembrolizumab alone—confirming and strengthening the earlier Phase IIb findings.
This approach represents a shift from traditional “one-size-fits-all” cancer treatments toward highly individualized therapies. The mRNA-4157 vaccine is designed using each patient’s tumor genetic profile. By sequencing the tumor, scientists identify neoantigens—unique mutations present only in cancer cells. The vaccine then trains the immune system to recognize and attack those specific targets, essentially turning the patient’s own immune system into a precision-guided anti-cancer tool.
When combined with pembrolizumab, a checkpoint inhibitor that helps the immune system stay active against cancer cells, the effect becomes synergistic. While pembrolizumab removes the “brakes” on immune responses, mRNA-4157 provides a “roadmap,” directing immune cells toward the most relevant tumor-specific threats. This dual mechanism appears to be key to the improved recurrence-free survival observed in the trial.
The KEYNOTE-942 enrolled patients with high-risk melanoma who had already undergone surgical removal of their tumors but remained at significant risk of relapse. These patients historically face limited options beyond standard immunotherapy. The addition of a personalized vaccine introduces a new layer of protection during this critical post-surgical period.
Importantly, the safety profile of the combination therapy was consistent with previous studies, with manageable side effects and no unexpected toxicities. This reinforces the feasibility of integrating personalized mRNA vaccines into existing cancer treatment regimens.
Beyond melanoma, these findings have broader implications. The success of mRNA-4157 underscores the potential of mRNA technology—previously proven in infectious diseases—to transform oncology. It opens the door to similar personalized vaccines across multiple cancer types, particularly those driven by identifiable mutations.
